Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 16/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 10/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150273 | 0.87 | DUT (0.52) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL7745800 | 0.87 | DUT (0.55) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL1129336 | 0.87 | DUT (0.52) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8441083 | 0.87 | DUT (0.52) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8439797 | 0.85 | DUT (0.51) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL1129230 | 0.84 | DUT (0.54) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL14855438 | 0.84 | DUT (0.50) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8436034 | 0.84 | DUT (0.52) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL4719489 | 0.84 | P2RY2 (0.49) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8441386 | 0.83 | DUT (0.51) | DUTP2RY2P2RY4P2RY6POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3060671-A1 | CNS DELIVERY OF MRNA AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061461-A1 | CNS DELIVERY OF MRNA AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2015-04-30 | — | — | WO | disclosed |